Saniona AB (publ) (SANION.ST)
SEK 8.25
(12.09%)
SEK 8.25
(12.09%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -95.81 Million SEK | 60.95% |
| 2022 | -245.35 Million SEK | 40.29% |
| 2021 | -410.89 Million SEK | -459.58% |
| 2020 | -73.43 Million SEK | 3.11% |
| 2019 | -75.78 Million SEK | -84.58% |
| 2018 | -41.05 Million SEK | 16.53% |
| 2017 | -49.18 Million SEK | -2318.72% |
| 2016 | 2.21 Million SEK | 109.66% |
| 2015 | -22.94 Million SEK | -288.41% |
| 2014 | -5.9 Million SEK | -358.18% |
| 2013 | -1.28 Million SEK | 22.06% |
| 2012 | -1.65 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.23 Million SEK | 67.86% |
| 2024 Q2 | -19.73 Million SEK | -113.63% |
| 2023 Q3 | -24.09 Million SEK | -13.47% |
| 2023 Q2 | -21.23 Million SEK | 2.36% |
| 2023 Q4 | -28.74 Million SEK | -19.3% |
| 2023 FY | -95.81 Million SEK | 60.95% |
| 2023 Q1 | -21.74 Million SEK | 46.9% |
| 2022 Q2 | -88.56 Million SEK | 33.59% |
| 2022 FY | -245.35 Million SEK | 40.29% |
| 2022 Q1 | -133.35 Million SEK | -2.95% |
| 2022 Q4 | -40.94 Million SEK | -333.77% |
| 2022 Q3 | 17.51 Million SEK | 119.78% |
| 2021 FY | -410.89 Million SEK | -459.58% |
| 2021 Q1 | -83.38 Million SEK | -290.27% |
| 2021 Q4 | -129.53 Million SEK | -30.71% |
| 2021 Q3 | -99.09 Million SEK | 4.66% |
| 2021 Q2 | -103.94 Million SEK | -24.66% |
| 2020 FY | -73.43 Million SEK | 3.11% |
| 2020 Q4 | 43.82 Million SEK | 183.24% |
| 2020 Q1 | -28.18 Million SEK | -718.11% |
| 2020 Q2 | -36.42 Million SEK | -29.23% |
| 2020 Q3 | -52.65 Million SEK | -44.56% |
| 2019 Q2 | -19.79 Million SEK | 20.22% |
| 2019 Q4 | -3.44 Million SEK | 87.58% |
| 2019 Q3 | -27.74 Million SEK | -40.16% |
| 2019 FY | -75.78 Million SEK | -84.58% |
| 2019 Q1 | -24.81 Million SEK | -6.29% |
| 2018 Q4 | -23.34 Million SEK | -252.6% |
| 2018 Q2 | -19.56 Million SEK | -45.41% |
| 2018 Q1 | -13.45 Million SEK | 8.86% |
| 2018 Q3 | 15.29 Million SEK | 178.2% |
| 2018 FY | -41.05 Million SEK | 16.53% |
| 2017 Q2 | -14.69 Million SEK | -130.75% |
| 2017 Q4 | -14.75 Million SEK | -10.36% |
| 2017 Q1 | -6.36 Million SEK | 48.97% |
| 2017 Q3 | -13.37 Million SEK | 8.98% |
| 2017 FY | -49.18 Million SEK | -2318.72% |
| 2016 Q2 | -10.27 Million SEK | -320.08% |
| 2016 Q1 | -2.44 Million SEK | 48.97% |
| 2016 FY | 2.21 Million SEK | 109.66% |
| 2016 Q4 | -12.47 Million SEK | -145.52% |
| 2016 Q3 | 27.4 Million SEK | 366.85% |
| 2015 Q3 | -7.95 Million SEK | -45.5% |
| 2015 Q4 | -4.79 Million SEK | 39.8% |
| 2015 FY | -22.94 Million SEK | -288.41% |
| 2015 Q1 | -4.72 Million SEK | -6.44% |
| 2015 Q2 | -5.47 Million SEK | -15.72% |
| 2014 Q3 | -1.85 Million SEK | -122.78% |
| 2014 FY | -5.9 Million SEK | -358.18% |
| 2014 Q4 | -4.44 Million SEK | -139.02% |
| 2014 Q1 | -401 Thousand SEK | 0.0% |
| 2014 Q2 | -834 Thousand SEK | -107.98% |
| 2013 FY | -1.28 Million SEK | 22.06% |
| 2012 FY | -1.65 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | -109.192% |
| Biovica International AB (publ) | -124.82 Million SEK | 23.243% |
| Cantargia AB (publ) | -280.02 Million SEK | 65.785% |
| CombiGene AB (publ) | -35.66 Million SEK | -168.636% |
| Cyxone AB (publ) | -22.98 Million SEK | -316.765% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -720.432% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -484.279% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -4.824% |
| Fluicell AB (publ) | -26.55 Million SEK | -260.812% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 22.149% |
| Mendus AB (publ) | -101.61 Million SEK | 5.716% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -158.45% |
| I-Tech AB | 20.2 Million SEK | 574.236% |
| Intervacc AB (publ) | -102.85 Million SEK | 6.847% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -689.99% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 887.328% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -435.341% |
| OncoZenge AB (publ) | -15.9 Million SEK | -502.503% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -21774.429% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 75.318% |
| Lipum AB (publ) | -37.17 Million SEK | -157.706% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 61.458% |
| Ziccum AB (publ) | -21.41 Million SEK | -347.459% |
| BioArctic AB (publ) | 229.24 Million SEK | 141.793% |
| Genovis AB (publ.) | 61.5 Million SEK | 255.789% |
| Camurus AB (publ) | 431.44 Million SEK | 122.207% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 46.125% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -68.617% |
| Aptahem AB (publ) | -11.11 Million SEK | -762.154% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 69.187% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 46.674% |
| Kancera AB (publ) | -64.88 Million SEK | -47.652% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -126.914% |
| AcouSort AB (publ) | -17.08 Million SEK | -460.653% |
| Xintela AB (publ) | -54.08 Million SEK | -77.154% |
| Abliva AB (publ) | -95.5 Million SEK | -0.315% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 1878.871% |
| Amniotics AB (publ) | -30.87 Million SEK | -210.366% |
| 2cureX AB (publ) | -32.51 Million SEK | -194.637% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -646.882% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 79.448% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 88.48% |
| Biosergen AB | -27.03 Million SEK | -254.366% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -479.858% |
| Corline Biomedical AB | -1.8 Million SEK | -5196.296% |
| NextCell Pharma AB | -41.95 Million SEK | -128.338% |
| Nanologica AB (publ) | -75.15 Million SEK | -27.48% |
| LIDDS AB (publ) | -40.2 Million SEK | -138.298% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 70.691% |
| BioInvent International AB (publ) | -330.3 Million SEK | 70.993% |
| SynAct Pharma AB | -215.81 Million SEK | 55.604% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -117.483% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -303.632% |
| Alzinova AB (publ) | -16.48 Million SEK | -481.371% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 12.333% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 61.539% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -864.853% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 15.454% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -354.27% |
| Simris Alg AB (publ) | -37.3 Million SEK | -156.829% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 36.905% |